At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,307 enrolled
Drug / intervention
SB204 4% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Multi-Center, Randomized, Double-Blinded, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy, Tolerability and Safety of SB204 and Vehicle Gel Once Daily in the Treatment of Acne Vulgaris
In Brief
A Phase 3 clinical trial evaluating SB204 4% and Vehicle Gel for Acne Vulgaris. Completed, enrolled 1,307 participants across 55 sites.
Detailed Summary
This is a 12 week, multi-center, double-blinded, randomized, vehicle-controlled, parallel group, study to be conducted in approximately 1300 subjects with acne vulgaris in the US.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States
CollaboratorsChiltern International Inc.
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 2016
Enrollment StartFeb 2016
Primary CompletionDec 2016
Study CompletionDec 2016
TodayJul 2026
First PostedFeb 3, 2016
Enrollment StartFeb 22, 2016
Primary CompletionDec 1, 2016
Study CompletionDec 21, 2016
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 10.4 years ago
Interventions
SB204 4%drug
Once daily
Vehicle Geldrug
Placebo comparator